Literature DB >> 20018935

Local atherosclerotic plaques are a source of prognostic biomarkers for adverse cardiovascular events.

Dominique P V de Kleijn1, Frans L Moll, Willem E Hellings, Gonen Ozsarlak-Sozer, Peter de Bruin, Pieter A Doevendans, Aryan Vink, Louise M Catanzariti, Arjan H Schoneveld, Ale Algra, Mat J Daemen, E A Biessen, W de Jager, Huoming Zhang, Jean-Paul de Vries, Erling Falk, Sai K Lim, Peter J van der Spek, Siu Kwan Sze, Gerard Pasterkamp.   

Abstract

OBJECTIVE: Atherosclerotic cardiovascular disease is a major burden to health care. Because atherosclerosis is considered a systemic disease, we hypothesized that one single atherosclerotic plaque contains ample molecular information that predicts future cardiovascular events in all vascular territories. METHODS AND
RESULTS: AtheroExpress is a biobank collecting atherosclerotic lesions during surgery, with a 3-year follow-up. The composite primary outcome encompasses all cardiovascular events and interventions, eg, cardiovascular death, myocardial infarction, stroke, and endovascular interventions. A proteomics search identified osteopontin as a potential plaque biomarker. Patients undergoing carotid surgery (n=574) served as the cohort in which plaque osteopontin levels were examined in relation to their outcome during follow-up and was validated in a cohort of patients undergoing femoral endarterectomy (n=151). Comparing the highest quartile of carotid plaque osteopontin levels with quartile 1 showed a hazard ratio for the primary outcome of 3.8 (95% confidence interval, 2.6-5.9). The outcome did not change after adjustment for plaque characteristics and traditional risk factors (hazard ratio, 3.5; 95% confidence interval, 2.0-5.9). The femoral validation cohort showed a hazard ratio of 3.8 (95% confidence interval 2.0 to 7.4) comparing osteopontin levels in quartile 4 with quartile 1.
CONCLUSIONS: Plaque osteopontin levels in single lesions are predictive for cardiovascular events in other vascular territories. Local atherosclerotic plaques are a source of prognostic biomarkers with a high predictive value for secondary manifestations of atherosclerotic disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20018935     DOI: 10.1161/ATVBAHA.109.194944

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  25 in total

1.  Protein biomarkers for the prediction of cardiovascular disease in type 2 diabetes.

Authors:  Helen C Looker; Marco Colombo; Felix Agakov; Tanja Zeller; Leif Groop; Barbara Thorand; Colin N Palmer; Anders Hamsten; Ulf de Faire; Everson Nogoceke; Shona J Livingstone; Veikko Salomaa; Karin Leander; Nicola Barbarini; Riccardo Bellazzi; Natalie van Zuydam; Paul M McKeigue; Helen M Colhoun
Journal:  Diabetologia       Date:  2015-03-05       Impact factor: 10.122

2.  Plaque Composition in the Proximal Superficial Femoral Artery and Peripheral Artery Disease Events.

Authors:  Mary M McDermott; Christopher M Kramer; Lu Tian; James Carr; Jack M Guralnik; Tamar Polonsky; Timothy Carroll; Melina Kibbe; Michael H Criqui; Luigi Ferrucci; Lihui Zhao; Daniel S Hippe; John Wilkins; Dongxiang Xu; Yihua Liao; Walter McCarthy; Chun Yuan
Journal:  JACC Cardiovasc Imaging       Date:  2016-11-09

3.  Osteopontin predicts long-term functional outcome among ischemic stroke patients.

Authors:  M Mendioroz; I Fernández-Cadenas; A Rosell; P Delgado; S Domingues-Montanari; M Ribó; A Penalba; M Quintana; J Alvarez-Sabín; J Montaner
Journal:  J Neurol       Date:  2010-10-22       Impact factor: 4.849

4.  10-years experience with the Athero-Express study.

Authors:  Willem E Hellings; Frans L Moll; Dominique P V de Kleijn; Gerard Pasterkamp
Journal:  Cardiovasc Diagn Ther       Date:  2012-03

Review 5.  Insight of brain degenerative protein modifications in the pathology of neurodegeneration and dementia by proteomic profiling.

Authors:  Sunil S Adav; Siu Kwan Sze
Journal:  Mol Brain       Date:  2016-11-03       Impact factor: 4.041

6.  Atherosclerotic plaque biomarkers: beyond the horizon of the vulnerable plaque.

Authors:  Guus W van Lammeren; Frans L Moll; Gert Jan De Borst; Dominique P V de Kleijn; Jean-Paul P M de Vries; Gerard Pasterkamp
Journal:  Curr Cardiol Rev       Date:  2011-02

7.  Atherosclerosis: from biology to pharmacological treatment.

Authors:  Graziano Riccioni; Valeriana Sblendorio
Journal:  J Geriatr Cardiol       Date:  2012-09       Impact factor: 3.327

8.  Antibody phage display assisted identification of junction plakoglobin as a potential biomarker for atherosclerosis.

Authors:  Seraina Cooksley-Decasper; Hans Reiser; Daniela S Thommen; Barbara Biedermann; Michel Neidhart; Joanna Gawinecka; Gieri Cathomas; Fabian C Franzeck; Christophe Wyss; Roland Klingenberg; Paolo Nanni; Bernd Roschitzki; Christian Matter; Petra Wolint; Maximilian Y Emmert; Marc Husmann; Beatrice Amann-Vesti; Wilibald Maier; Steffen Gay; Thomas F Lüscher; Arnold von Eckardstein; Danielle Hof
Journal:  PLoS One       Date:  2012-10-24       Impact factor: 3.240

9.  Plasma levels of osteopontin identify patients at risk for organ damage in systemic lupus erythematosus.

Authors:  Ornella J Rullo; Jennifer M P Woo; Miriam F Parsa; Alice D C Hoftman; Paul Maranian; David A Elashoff; Timothy B Niewold; Jennifer M Grossman; Bevra H Hahn; Maureen McMahon; Deborah K McCurdy; Betty P Tsao
Journal:  Arthritis Res Ther       Date:  2013-01-23       Impact factor: 5.156

10.  Carotid atherosclerotic plaque matrix metalloproteinase-12-positive macrophage subpopulation predicts adverse outcome after endarterectomy.

Authors:  Vincent P W Scholtes; Jason L Johnson; Nicholas Jenkins; Graciela B Sala-Newby; Jean-Paul P M de Vries; Gert Jan de Borst; Dominique P V de Kleijn; Frans L Moll; Gerard Pasterkamp; Andrew C Newby
Journal:  J Am Heart Assoc       Date:  2012-12-19       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.